Women in Life Science Denmark announce The First Women in Leadership Network to Support Diversity, Equality and Inclusion across the Life Sciences Industry launched in Denmark

/in

New Professional Network for Female Executives and Specialists to Elevate and Promote Female Talents across the Life Sciences industry in Denmark  Supported by the Novo Nordisk Foundation Women in Life Science Denmark (WiLD), an inspiring and science-centric not-for-profit network for women in senior positions across industry and academia launched in January 2023 to strengthen value creation in […]

Read more

Structural proteins for the development of sustainable materials: BRAIN Biotech and AMSilk cooperate to develop high-performance bio-based protein fibers

/in

Zwingenberg/Neuried, February 8, 2023 – Creating a better future with biotechnology – this vision is shared by BRAIN Biotech AG (BRAIN Biotech), a leader in the development and manufacture of bio-based solutions and products for industry, and AMSilk GmbH (AMSilk), the world’s first industrial supplier of innovative biomaterials for more sustainable applications in the textile, medical […]

Read more

Sequana Medical announces the successful completion of pre-clinical studies with its second-generation DSR product for congestive heart failure

/in

Data from GLP[i] animal studies demonstrate safety of second-generation DSR[ii] product (DSR 2.0) Data from Phase 1 study of DSR 2.0 in Mexico (CHIHUAHUA) and IND[iii] filing to US FDA expected in Q1 2023 Planning to start MOJAVE, a US Phase 1/2a randomized controlled multi-center study of DSR 2.0, in Q2 2023 Ghent, Belgium – 08 February 2023 – Sequana […]

Read more

Chong Kun Dang Pharm Licenses Synaffix ADC Technology, Adds Novel ADC Candidate to Oncology Pipeline

/in

   Synaffix to provide access to proprietary Antibody-Drug Conjugate (ADC) technologies Single-target license with upfront and milestone payments plus royalties First Synaffix partnership announced with a Korean company Read more…

Read more

Sequana Medical announces grant of additional DSR® patent in United States

/in

Ghent, Belgium – 1 February 2023 – Sequana Medical NV (Euronext Brussels: SEQUA) (the “Company” or “Sequana Medical“), a pioneer in the treatment of fluid overload in liver disease, heart failure and cancer, today announces the grant of an additional US patent for its DSR (Direct Sodium Removal) program. Read more…

Read more